Landogrozumab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameLandogrozumab
Drug Alias NameLY-2495655
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionGrowth/differentiation factor 8 inhibitors
TargetsGrowth/differentiation factor 8
Therapy Area/IndicationsMuscular AtrophyMuscle WeaknessPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsMuscular AtrophyMuscle WeaknessPancreatic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia